Reframe vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 56)
Reframe logo

Reframe

ChallengerHealthcare

General

SF YC W21 alcohol reduction app at $13M ARR with 150K+ paying customers; $17.4M Series B Goodwater 2022 with neuroscience-based CBT and community support competing with Monument for gray-area drinker digital behavior change.

AI VisibilityBeta
Overall Score
C56
Category Rank
#162 of 596
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
59
Perplexity
58
Gemini
61

About

Reframe (formerly Glucobit) is a San Francisco-based digital health platform — backed by Y Combinator (W21) — providing people seeking to quit or reduce alcohol consumption with a neuroscience-based mobile app that combines behavioral psychology, habit tracking, and community support, achieving $13 million in annual revenue with 150,000+ paying customers after 10x growth in 12 months and 3,000% growth in 6 months to become one of the top health apps on the App Store. Founded in 2018 by Ziyi Gao and Vedant Pradeep, Reframe raised $17.4 million in a Series B in January 2022 from Goodwater Capital, applying evidence-based alcohol reduction techniques (including CBT, mindfulness, and neuroscience education about alcohol's brain effects) to the 30 million Americans who want to drink less but don't seek traditional addiction treatment.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

56
Overall Score
93
#162
Category Rank
#1
86
AI Consensus
80
stable
Trend
up
59
ChatGPT
94
58
Perplexity
89
61
Gemini
94
55
Claude
92
59
Grok
98

Key Details

Category
General
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.